HRASLS2 Inhibitors
HRASLS2 inhibitors encompass a range of compounds that affect the activity of HRASLS2, a phospholipase with an important role in lipid metabolism and signaling. The inhibition of HRASLS2 can be achieved through several indirect mechanisms involving different molecular targets and pathways.
Celecoxib and Indomethacin are examples of nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX) enzymes. These enzymes are critical in the production of prostaglandins, which are lipid compounds that perform various functions including inflammation and pain modulation. By inhibiting COX enzymes, these drugs reduce prostaglandin levels, which in turn limits the availability of substrates that HRASLS2 requires for its lipid-modifying activities. This indirect inhibition can lead to decreased HRASLS2 function due to a lower concentration of its substrates.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Indomethacin | 53-86-1 | sc-200503 sc-200503A | 1 g 5 g | $29.00 $38.00 | 18 | |
A nonselective COX inhibitor that blocks the conversion of arachidonic acid to prostaglandins. With HRASLS2's role in arachidonic acid mobilization, Indomethacin's action would result in reduced substrate access for HRASLS2, indirectly inhibiting its function. | ||||||
Manumycin A | 52665-74-4 | sc-200857 sc-200857A | 1 mg 5 mg | $219.00 $634.00 | 5 | |
A farnesyltransferase inhibitor that prevents the farnesylation of proteins like HRAS. As HRASLS2 shares homology with HRAS, Manumycin A might inhibit HRASLS2 directly or alter its localization and function. | ||||||
Zileuton | 111406-87-2 | sc-204417 sc-204417A sc-204417B sc-204417C | 10 mg 50 mg 1 g 75 g | $84.00 $307.00 $369.00 $1254.00 | 8 | |
A 5-lipoxygenase inhibitor that prevents the synthesis of leukotrienes from arachidonic acid. By inhibiting leukotriene synthesis, Zileuton could reduce the biological activity of HRASLS2 in leukotriene pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that can lead to reduced phosphorylation of downstream targets within the PI3K/Akt pathway. If HRASLS2 function is regulated by this pathway, LY294002 would indirectly inhibit its activity. | ||||||
NDGA (Nordihydroguaiaretic acid) | 500-38-9 | sc-200487 sc-200487A sc-200487B | 1 g 5 g 25 g | $109.00 $384.00 $2190.00 | 3 | |
A lipoxygenase inhibitor that reduces the metabolism of polyunsaturated fatty acids. HRASLS2, which may function in pathways utilizing these fatty acids, would have less substrate availability due to NDGA, indirectly inhibiting its functional activity. | ||||||